ResearchMoz

Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape

GBI Research
Published Date » 2014-01-31
No. Of Pages » 120
   
 GBI Research, has released the pharma report – “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape”. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Signs and Symptoms
2.2 Etiology and Risk Factors
2.3 Pathophysiology
2.4 Epidemiology
2.4.1 US and Canada
2.4.2 Europe
2.4.3 Japan
2.4.4 Regional Prevalence of Hepatitis C Genotypes
2.5 Prognosis
2.6 Diagnosis and Screening
2.7 Treatment
2.8 Treatment Algorithms

3 Marketed Products
3.1 Ribavirin
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) – Hoffmann La Roche and Merck & Co
3.2.1 Pegasys – Hoffmann La Roche
3.2.2 PegIntron – Merck & Co
3.3 Incivek (telaprevir) – Vertex Pharmaceuticals and Janssen-Cilag
3.4 Victrelis (boceprevir) – Merck & Co
3.5 Olysio (simeprevir) – Johnson and Johnson
3.6 Sovaldi (sofosbuvir) – Gilead Sciences
3.7 Heat Map for Marketed Products

4 Developmental Pipeline
4.1 Overall Pipeline
4.2 Mechanisms of Action
4.3 Clinical Trials
4.3.1 Clinical Trial Failure Rates
4.3.2 Clinical Trial Enrollment
4.3.3 Clinical Trial Duration
4.3.4 Clinical Trial Design
4.4 Promising Pipeline Drugs
4.4.1 Sovaldi plus Ledipasvir – Gilead Sciences
4.4.2 Daclatasvir – Bristol-Myers Squibb
4.4.3 Faldaprevir – Boehringer-Ingelheim
4.4.4 Peginterferon lambda 1a – Bristol-Myers Squibb
4.4.5 ABT-450 – AbbVie and Enanta
4.4.6 Vaniprevir – Merck & Co
4.5 Heat Map and Competitor Matrix for Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Global Market
5.1.1 Treatment Usage Patterns
5.1.2 Market Size
5.2 US
5.2.1 Treatment Usage Patterns
5.2.2 Market Size
5.3 Canada
5.3.1 Treatment Usage Patterns
5.3.2 Market Size
5.4 Top Five European Markets
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Market Size

6 Drivers and Barriers
6.1 Drivers
6.1.1 Approval of Sovaldi and Olysio in 2013
6.1.2 Large and Exceptionally Promising Late-Stage Pipeline
6.1.3 Favorable Pricing Structure in the US
6.1.4 Weak Exposure to Generics and Biosimilars during the Forecast Period
6.1.5 Increasing Volume of Treated Patients
6.1.6 Rapid Incorporation of Novel Products into Treatment Guidelines
6.2 Barriers
6.2.1 Low Rates of Diagnosis and Treatment in Certain Markets
6.2.2 Unfavorable Pricing Structures in the EU and Japan
6.2.3 Rapidly Increasing Competition in the Market

7 Licensing and Co-development deals
7.1 Licensing Deals
7.1.1 Vertex Pharma Enters into Licensing Agreement with Alios BioPharma for ALS-2200 and ALS-2158
7.1.2 Bristol-Myers Squibb Company Enters into Licensing Agreement with ZymoGenetics
7.1.3 Human Genome Sciences Enters Into Licensing Agreement With Novartis
7.1.4 Roche Signs Licensing Agreement With InterMune
7.1.5 Idenix Enters Into A Licensing Agreement With Novartis Pharma
7.1.6 Enanta Pharma Enters into Licensing Agreement with Novartis for Hepatitis C Program
7.1.7 Medivir Enters into Licensing Agreement with Tibotec
7.1.8 Metabasis Therapeutics Enters Into Collaboration And Licensing Agreement With Roche
7.1.9 Schering-Plough And PTC Therapeutics Enter Into A Collaboration And Licensing Agreement
7.1.10 Presidio Pharma Enters into Licensing Agreement with XTL BioPharma
7.2 Co-development Deals
7.2.1 Vertex Pharma Enters into Co-Development Agreement with Janssen Pharmaceutica
7.2.2 Abbott Labs Enters into Agreement with Enanta Pharma
7.2.3 Genelabs Enters into Collaboration with Novartis
7.2.4 Regulus Therapeutics Enters into an Agreement with GlaxoSmithKline
7.2.5 Tacere Therapeutics Enters into Agreement with Pfizer
7.2.6 Biota Holdings Enters into an Agreement with Boehringer Ingelheim

8 Appendix
8.1 Sources
8.2 Sources for Heat Maps
8.3 All Pipeline Products, by Stage of Development
8.3.1 Discovery
8.3.2 Preclinical and IND/CTA-filed
8.3.3 Phase I
8.3.4 Phase II
8.3.5 Phase III and Pre-registration
8.3.6 Undisclosed
8.4 Tabular Forecast Data
8.4.1 Global
8.4.2 US
8.4.3 Canada
8.4.4 UK
8.4.5 France
8.4.6 Germany
8.4.7 Italy
8.4.8 Spain
8.4.9 Japan
8.5 Market Definition
8.6 Abbreviations
8.7 Methodology
8.7.1 Coverage
8.7.2 Secondary Research
8.7.3 Primary Research
8.7.4 Therapeutic Landscape
8.7.5 Epidemiology-Based Forecasting
8.7.6 Market Size by Geography
8.7.7 Geographical Landscape
8.7.8 Pipeline Analysis
8.8 Contact Us
8.9 Disclaimer

List of Tables

Table 1: Hepatitis C, Top Five European Countries, Disease Prevalence (%), 2011
Table 2: Hepatitis C, Top Five European Markets, Most Common Risk Factors for Infection (%), 2011
Table 3: Hepatitis C, Global, Estimated Distribution of Hepatitis C Genotypes (%), 2013
Table 4: Market for Hepatitis C, Sources for Heat Maps
Table 5: Hepatitis C Therapeutics, Global, All Pipeline Products (Discovery), 2013
Table 6: Hepatitis C Therapeutics, Global, All Pipeline Products (Preclinical and IND/CTA-filed), 2013
Table 7: Hepatitis C, Global, All Pipeline Products (Phase I), 2013
Table 8: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase II), 2013
Table 9: Hepatitis C Therapeutics, Global, All Pipeline Products (Phase III), 2013
Table 10: Hepatitis C Therapeutics, Global, All Pipeline Products (Undisclosed), 2013
Table 11: Market for Hepatitis C, Global, Forecast Data, 2012–2019
Table 12: Market for Hepatitis C, US, Forecast Data, 2012–2019
Table 13: Market for Hepatitis C, Canada, Forecast Data, 2012–2019
Table 14: Market for Hepatitis C, UK, Forecast Data, 2012–2019
Table 15: Market for Hepatitis C, France, Forecast Data, 2012–2019
Table 16: Market for Hepatitis C, Germany, Forecast Data, 2012–2019
Table 17: Market for Hepatitis C, Italy, Forecast Data, 2012–2019
Table 18: Market for Hepatitis C, Spain, Forecast Data, 2012–2019
Table 19: Market for Hepatitis C, Japan, Forecast Data, 2012–2019

List of Figures

Figure 1: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Incivek), 2013
Figure 2: Market for Hepatitis C, Global, Treatment Algorithm (Genotype 1, Triple Therapy with Victrelis), 2013
Figure 3: Market for Hepatitis C, Global, Treatment Algorithm (Genotypes 2 to 7), 2013
Figure 4: Market for Hepatitis C, Global, Sales of Pegasys and PegIntron ($m), 2002–2012
Figure 5: Market for Hepatitis C, Global, Heat Map for Marketed Products, 2013
Figure 6: Market for Hepatitis C, Global, Developmental Pipeline, 2013
Figure 7: Market for Hepatitis C, Global, Pipeline by Mechanism of Action and Molecule Type, 2013
Figure 8: Market for Hepatitis C, Global, Clinical Trial Failure Rate by Molecule Type, 2006–2013
Figure 9: Market for Hepatitis C, Global, Clinical Trial Failure Rates by Mechanism of Action, 2006–2013
Figure 10: Market for Hepatitis C, Global, Clinical Trial Enrollment by Molecule Type, 2006–2013
Figure 11: Market for Hepatitis C, Global, Clinical Trial Enrollment by Mechanism of Action, 2006–2013
Figure 12: Market for Hepatitis C, Clinical Trial Duration by Molecule Type, 2006–2013
Figure 13: Market for Hepatitis C, Global, Clinical Trial Duration by Mechanism of Action, 2006–2013
Figure 14: Market for Hepatitis C, Global, Frequency of Clinical Trial Primary Endpoints Per Clinical Trial, 2006–2013
Figure 15: Market for Hepatitis C, Global, Frequency of Clinical Trial Endpoints Primary within Clinical Development Programs, 2006–2013
Figure 16: Market for Hepatitis C, Global, Usage of HCV Genotypes as Clinical Trial Inclusion Criteria, 2006–2013
Figure 17: Market for Hepatitis C, Global, Sales Forecast for Sovaldi plus ledipasvir ($m), 2015–2019
Figure 18: Market for Hepatitis C, Global, Sales Forecast for daclatasvir (monotherapy) ($m), 2015–2019
Figure 19: Market for Hepatitis C, Global, Sales Forecast for daclatasvir plus asunaprevir plus BMS-791325 ($m), 2015–2019
Figure 20: Market for Hepatitis C, Global, Sales Forecast for faldaprevir ($m), 2015–2019
Figure 21: Market for Hepatitis C, Global, Sales Forecast for peginterferon lambda 1a ($m), 2015–2019
Figure 22: Market for Hepatitis C, Global, Sales Forecast for ABT-450 ($m), 2015–2019
Figure 23: Market for Hepatitis C, Global, Sales Forecast for ABT-450 plus ABT-333 plus ABT-267 ($m), 2015–2019
Figure 24: Market for Hepatitis C, Global, Sales Forecast for vaniprevir, 2015–2019
Figure 25: Market for Hepatitis C, Global, Heat Map for Pipeline Products, 2013
Figure 26: Market for Hepatitis C, Global, Competitor Matrix, 2013
Figure 27: Market for Hepatitis C, Global, Market Growth and Size, 2012–2019
Figure 28: Market for Hepatitis C, Global, Treatment Patterns, 2012–2019
Figure 29: Market for Hepatitis C, Global, Market Size ($bn), 2012–2019
Figure 30: Market for Hepatitis C, US, Treatment Usage Patterns, 2012–2019
Figure 31: Market for Hepatitis C, US, Market Size ($bn), 2012–2019
Figure 32: Market for Hepatitis C, Canada, Treatment Usage Patterns, 2012–2019
Figure 33: Market for Hepatitis C, Canada, Market Size ($m), 2012–2019
Figure 34: Market for Hepatitis C, Top Five European Markets, Treatment Patterns, 2012–2019
Figure 35: Market for Hepatitis C, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019
Figure 36: Market for Hepatitis C, Top Five European Markets, Market Size ($m), 2012–2019
Figure 37: Market for Hepatitis C, Japan, Treatment Usage Patterns, 2012–2019
Figure 38: Market for Hepatitis C, Japan, Market Size ($m), 2012–2019
Figure 39: Market for Hepatitis C, Global, Network of Licensing Deals, 2006–2013
Figure 40: Market for Hepatitis C, Global, Licensing Deals by Year, 2006–2013
Figure 41: Market for Hepatitis C, Global, Licensing Deals, 2006–2013
Figure 42: Market for Hepatitis C, Global, Network of Co-Development Deals, 2006–2013
Figure 43: Market for Hepatitis C, Global, Co-Development Deals by Year, 2006–2013
Figure 44: GBI Research Market Forecasting Model

Upcoming Reports:

UV Curable Inks Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020
By - Transparency Market Research
Ultraviolet curing (UV curing) is a photochemical process wherein high intensity UV light is used to cure or dry inks, adhesives or coatings. UV curable inks speed up the printing process by reducing the drying time while facilitating superior bonding. UV curable inks do not employ the use of environmentally harmful solvents, additionally; they do not cause loss of coating thickness and volume loss in final prints. This causes a reduction in waste, pollutant emissions and energy use. UV curable inks are being increasingly used in printing applications as they offer higher productivity...
Healthcare Supplies Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts, 2012 - 2018
By - Transparency Market Research
The global demand for healthcare supplies is expected to increase in the near future due to the growing population and the increasing need for better healthcare services. There is a rising demand for home healthcare facilities, which is a prominent reason for the growth of this market. Product innovation is also expected to contribute effectively and have an influence on the healthcare supplies industry. The increasing volume of patient care activity encouraged by an aging population and the rising incidences of diseases and disorders is promoting the growth of the healthcare supplies...
Magnetic Field Sensors Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Magnetic field sensors are used to detect position of any object based on magnetic field. For instance, movements of gear wheels inside gearbox create alteration in magnetic field helping the sensors to indentify location of position of objects. This collected information is further sent to integrated electronics to evaluate the condition of the respective objects or vehicle. Magnetic field sensors are of non-contact type and use digital or analog signals for data transmission based on their type. With the development of technology magnetic field sensors are being used in various...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
Samsung Records Poorest Profits in Q3 2014
Oct 29, 2014  
In the quarter ending September 2014, Samsung Electronics Co. Ltd registered the smallest earnings ever in two years. The drop in earnings can be easily attributed to heavy competition from new Chinese devices and the Apple phones. The net income stood at US$4 billion for the South Korea-based company. Apple has been Samsung’s strongest contender ever since the latter entered the...